In this preclinical study, we assessed feasibility of evaluating Gadolinium deposition in cortical bone by using recently developed actual flip angle variable repetition time 3D ultrashort echotime technique in rabbit model at 7T. Twenty times of administration of clinical equivalent dose of Magnevist and Gadovist that normalized according to body surface by U.S. FDA recommendation, and three times the dose of Gadovist (high-dose group) were investigated. Significant lower T1 values were observed in Magnevist administration group, Gadovist administration group and high-dose Gadovist administration group compared to control group, suggested T1 mapping might be a potential biomarker for evaluating Gadolinium deposition.
This abstract and the presentation materials are available to members only; a login is required.